Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity

9 Sept 2019

Abstract excerpt

Abstract Treatment of cancer with poly (ADP-ribose) polymerase (PARP) inhibitors is currently limited to cells defective in the homologous recombination (HR) pathway. Identification of genetic targets that induce or mimic HR deficiencies will extend the clinical utility of PARP inhibitors. Here we perform a CRISPR/Cas9-based genome-scale loss-of-function screen, using the sensitivity of PARP inhibitor olaparib as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31508509
DOI: 10.1038/s42003-019-0580-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivityPMID 31508509Read ↗

Metabolism‐focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancerSemantic proximity Read ↗

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor SensitivitySemantic proximity Read ↗

CHK2 inhibition provides a strategy to suppress hematological toxicity from PARP inhibitorsSemantic proximity Read ↗

Metabolism-focused CRISPR screen unveils Mitochondrial Pyruvate Carrier 1 as a critical driver for PARP inhibitor resistance in lung cancerSemantic proximity Read ↗

Identification of regulators of poly-ADP-ribose polymerase (PARP) inhibitor response through complementary CRISPR knockout and activation screensSemantic proximity Read ↗

CRISPR screens guide the way for PARP and ATR inhibitor biomarker discoverySemantic proximity Read ↗

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read ↗

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancerSemantic proximity Read ↗

Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacySemantic proximity Read ↗

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read ↗

Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics.Semantic proximity Read ↗

An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer DrugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.